Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cardiovascular Translational Research
Erschienen in: Journal of Cardiovascular Translational Research 4/2012

01.08.2012

MicroRNAs and Diabetic Complications

verfasst von: Rama Natarajan, Sumanth Putta, Mitsuo Kato

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Both Type 1 and Type 2 diabetes can lead to debilitating microvascular complications such as retinopathy, nephropathy and neuropathy, as well as macrovascular complications such as cardiovascular diseases including atherosclerosis and hypertension. Diabetic complications have been attributed to several contributing factors such as hyperglycemia, hyperlipidemia, advanced glycation end products, growth factors, and inflammatory cytokines/chemokines. However, current therapies are not fully efficacious and hence there is an imperative need for a better understanding of the molecular mechanisms underlying diabetic complications in order to identify newer therapeutic targets. microRNAs (miRNAs) are short non-coding RNAs that repress target gene expression via post-transcriptional mechanisms. Emerging evidence shows that they have diverse cellular and biological functions and play key roles in several diseases. In this review, we explore the role of miRNAs in the pathology of diabetic complications and also discuss the potential use of miRNAs as novel diagnostic and therapeutic targets for diabetic complications.
Literatur
1.
He, Z., & King, G. L. (2004). Microvascular complications of diabetes. Endocrinology and Metabolism Clinics of North America, 33, 215–238. xi-xii.PubMedCrossRef
2.
Beckman, J. A., Creager, M. A., & Libby, P. (2002). Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 287, 2570–2581.PubMedCrossRef
3.
Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54, 1615–1625.PubMedCrossRef
4.
King, G. L., Kunisaki, M., Nishio, Y., Inoguchi, T., Shiba, T., & Xia, P. (1996). Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes, 45(Suppl 3), S105–S108.PubMed
5.
Villeneuve, L. M., Reddy, M. A., & Natarajan, R. (2011). Epigenetics: deciphering its role in diabetes and its chronic complications. Clinical and Experimental Pharmacology and Physiology, 38, 401–409.PubMedCrossRef
6.
Cooper, M. E., & El-Osta, A. (2010). Epigenetics: mechanisms and implications for diabetic complications. Circulation Research, 107, 1403–1413.PubMedCrossRef
7.
8.
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.PubMedCrossRef
9.
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215–233.PubMedCrossRef
10.
Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.PubMedCrossRef
11.
He, L., & Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics, 5, 522–531.PubMedCrossRef
12.
Zamore, P. D., & Haley, B. (2005). Ribo-gnome: the big world of small RNAs. Science, 309, 1519–1524.PubMedCrossRef
13.
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843–854.PubMedCrossRef
14.
Wightman, B., Ha, I., & Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75, 855–862.PubMedCrossRef
15.
Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics, 9, 102–114.PubMedCrossRef
16.
Stefani, G., & Slack, F. J. (2008). Small non-coding RNAs in animal development. Nature Reviews Molecular Cell Biology, 9, 219–230.PubMedCrossRef
17.
Kim, V. N. (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nature Reviews Molecular Cell Biology, 6, 376–385.PubMedCrossRef
18.
Small, E. M., & Olson, E. N. (2011). Pervasive roles of microRNAs in cardiovascular biology. Nature, 469, 336–342.PubMedCrossRef
19.
Bhatt, K., Mi, Q. S., & Dong, Z. (2011). microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. American Journal of Physiology. Renal Physiology, 300, F602–F610.PubMedCrossRef
20.
Fernandez-Valverde, S. L., Taft, R. J., & Mattick, J. S. (2011). MicroRNAs in beta-cell biology, insulin resistance, diabetes and its complications. Diabetes, 60, 1825–1831.PubMedCrossRef
21.
Kato, M., Arce, L., & Natarajan, R. (2009). MicroRNAs and their role in progressive kidney diseases. Clinical Journal of the American Society of Nephrology, 4, 1255–1266.PubMedCrossRef
22.
Zhang, C. (2010). MicroRNAs in vascular biology and vascular disease. Journal of Cardiovascular Translational Research, 3, 235–240.PubMedCrossRef
23.
Kempen, J. H., O’Colmain, B. J., Leske, M. C., Haffner, S. M., Klein, R., Moss, S. E., et al. (2004). The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology, 122, 552–563.PubMedCrossRef
24.
Saaddine, J. B., Honeycutt, A. A., Narayan, K. M., Zhang, X., Klein, R., & Boyle, J. P. (2008). Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Archives of Ophthalmology, 126, 1740–1747.PubMedCrossRef
25.
Kovacs, B., Lumayag, S., Cowan, C., & Xu, S. (2011). MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Investigative Ophthalmology & Visual Science, 52, 4402–4409.CrossRef
26.
Feng, B., Chen, S., McArthur, K., Wu, Y., Sen, S., Ding, Q., et al. (2011). miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes, 60, 2975–2984.PubMedCrossRef
27.
McArthur, K., Feng, B., Wu, Y., Chen, S., & Chakrabarti, S. (2011). MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes, 60, 1314–1323.PubMedCrossRef
28.
Silva, V. A., Polesskaya, A., Sousa, T. A., Correa, V. M., Andre, N. D., Reis, R. I., et al. (2011). Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Molecular Vision, 17, 2228–2240.PubMed
29.
Kato, M., Park, J. T., & Natarajan, R. (2012) MicroRNAs and the glomerulus. Experimental Cell Research, 318, 993–1000.
30.
Ziyadeh, F. N., & Sharma, K. (2003). Overview: combating diabetic nephropathy. Journal of the American Society of Nephrology, 14, 1355–1357.PubMedCrossRef
31.
Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., et al. (2007). MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proceedings of the National Academy of Sciences of the United States of America, 104, 3432–3437.PubMedCrossRef
32.
Sharma, K., & Ziyadeh, F. N. (1995). Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes, 44, 1139–1146.PubMedCrossRef
33.
Yamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E., & Border, W. A. (1993). Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America, 90, 1814–1818.PubMedCrossRef
34.
Kato, M., Wang, L., Putta, S., Wang, M., Yuan, H., Sun, G., et al. (2010). Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. Journal of Biological Chemistry, 285, 34004–34015.PubMedCrossRef
35.
Kato, M., Arce, L., Wang, M., Putta, S., Lanting, L., & Natarajan, R. (2011). A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney International, 80, 358–368.PubMedCrossRef
36.
Kato, M., Putta, S., Wang, M., Yuan, H., Lanting, L., Nair, I., et al. (2009). TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nature Cell Biology, 11, 881–889.PubMedCrossRef
37.
Kato, M., & Natarajan, R. (2009). microRNA cascade in diabetic kidney disease: big impact initiated by a small RNA. Cell Cycle, 8, 3613–3614.PubMedCrossRef
38.
Wang, Q., Wang, Y., Minto, A. W., Wang, J., Shi, Q., Li, X., et al. (2008). MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. The FASEB Journal, 22, 4126–4135.CrossRef
39.
Wang, X. X., Jiang, T., Shen, Y., Caldas, Y., Miyazaki-Anzai, S., Santamaria, H., et al. (2010). Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes, 59, 2916–2927.PubMedCrossRef
40.
Long, J., Wang, Y., Wang, W., Chang, B. H., & Danesh, F. R. (2010). Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. Journal of Biological Chemistry, 285, 23457–23465.PubMedCrossRef
41.
Long, J., Wang, Y., Wang, W., Chang, B. H., & Danesh, F. R. (2011). MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. Journal of Biological Chemistry, 286, 11837–11848.PubMedCrossRef
42.
Wang, B., Komers, R., Carew, R., Winbanks, C. E., Xu, B., Herman-Edelstein, M., et al. (2012). Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. Journal of the American Society of Nephrology, 23, 252–265.PubMedCrossRef
43.
Krupa, A., Jenkins, R., Luo, D. D., Lewis, A., Phillips, A., & Fraser, D. (2010). Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. Journal of the American Society of Nephrology, 21, 438–447.PubMedCrossRef
44.
Wang, B., Herman-Edelstein, M., Koh, P., Burns, W., Jandeleit-Dahm, K., Watson, A., et al. (2010). E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes, 59, 1794–1802.PubMedCrossRef
45.
Wang, B., Koh, P., Winbanks, C., Coughlan, M. T., McClelland, A., Watson, A., et al. (2011). miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes, 60, 280–287.PubMedCrossRef
46.
Dey, N., Das, F., Mariappan, M. M., Mandal, C. C., Ghosh-Choudhury, N., Kasinath, B. S., et al. (2011). MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. Journal of Biological Chemistry, 286, 25586–25603.PubMedCrossRef
47.
Zhang, Z., Peng, H., Chen, J., Chen, X., Han, F., Xu, X., et al. (2009). MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Letters, 583, 2009–2014.PubMedCrossRef
48.
Fu, Y., Zhang, Y., Wang, Z., Wang, L., Wei, X., Zhang, B., et al. (2010). Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. American Journal of Nephrology, 32, 581–589.PubMedCrossRef
49.
Caporali, A., Meloni, M., Vollenkle, C., Bonci, D., Sala-Newby, G. B., Addis, R., et al. (2010). Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation, 123, 282–291.CrossRef
50.
Natarajan, R., & Nadler, J. L. (2004). Lipid inflammatory mediators in diabetic vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1542–1548.PubMedCrossRef
51.
Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813–820.PubMedCrossRef
52.
Devaraj, S., Dasu, M. R., & Jialal, I. (2010). Diabetes is a proinflammatory state: a translational perspective. Expert Review of Endocrinology and Metabolism, 5, 19–28.PubMed
53.
Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. Circulation, 105, 1135–1143.PubMedCrossRef
54.
Shan, Z. X., Lin, Q. X., Deng, C. Y., Zhu, J. N., Mai, L. P., Liu, J. L., et al. (2010). miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Letters, 584, 3592–3600.PubMedCrossRef
55.
Katare, R., Caporali, A., Zentilin, L., Avolio, E., Sala-Newby, G., Oikawa, A., et al. (2011). Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circulation Research, 108, 1238–1251.PubMedCrossRef
56.
Wang, X. H., Qian, R. Z., Zhang, W., Chen, S. F., Jin, H. M., & Hu, R. M. (2009). MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clinical and Experimental Pharmacology and Physiology, 36, 181–188.PubMedCrossRef
57.
Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 13, 613–618.PubMedCrossRef
58.
Feng, B., Chen, S., George, B., Feng, Q., & Chakrabarti, S. (2010). miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes/Metabolism Research and Reviews, 26, 40–49.PubMedCrossRef
59.
Shen, E., Diao, X., Wang, X., Chen, R., & Hu, B. (2011). MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. American Journal of Pathology, 179, 639–650.PubMedCrossRef
60.
Greco, S., Fasanaro, P., Castelvecchio, S., D’Alessandra, Y., Arcelli, D., Di Donato, M., et al. (2012). MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes (in press).
61.
van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences of the United States of America, 103, 18255–18260.PubMedCrossRef
62.
Duisters, R. F., Tijsen, A. J., Schroen, B., Leenders, J. J., Lentink, V., van der Made, I., et al. (2009). miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circulation Research, 104, 170–178. 176p following 178.PubMedCrossRef
63.
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456, 980–984.PubMedCrossRef
64.
Reddy, M. A., & Natarajan, R. (2011). Epigenetic mechanisms in diabetic vascular complications. Cardiovascular Research, 90, 421–429.PubMedCrossRef
65.
Shanmugam, N., Reddy, M. A., & Natarajan, R. (2008). Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. Journal of Biological Chemistry, 283, 36221–36233.PubMedCrossRef
66.
Villeneuve, L. M., Reddy, M. A., Lanting, L. L., Wang, M., Meng, L., & Natarajan, R. (2008). Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proceedings of the National Academy of Sciences of the United States of America, 105, 9047–9052.PubMedCrossRef
67.
Villeneuve, L. M., Kato, M., Reddy, M. A., Wang, M., Lanting, L., & Natarajan, R. (2010). Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes, 59, 2904–2915.PubMedCrossRef
68.
Reddy, M. A., Jin, W., Villeneuve, L., Wang, M., Lanting, L., Todorov, I., et al. (2012). Pro-inflammatory role of MicroRNA-200 in vascular smooth muscle cells from diabetic mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 32, 721–729.PubMedCrossRef
69.
Jin, W., Reddy, M. A., Chen, Z., Putta, S., Lanting, L., Kato, M., et al. (2012). Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. Journal of Biological Chemistry (in press).
70.
Thomas, M. C., Groop, P. H., & Tryggvason, K. (2012). Towards understanding the inherited susceptibility for nephropathy in diabetes. Current Opinion in Nephrology and Hypertension, 21, 195–202.PubMedCrossRef
71.
Bruno, A. E., Li, L., Kalabus, J. L., Pan, Y., Yu, A., & Hu, Z. (2012). miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3′UTRs of human genes. BMC Genomics, 13, 44.PubMedCrossRef
72.
Sun, G., Yan, J., Noltner, K., Feng, J., Li, H., Sarkis, D. A., et al. (2009). SNPs in human miRNA genes affect biogenesis and function. RNA, 15, 1640–1651.PubMedCrossRef
73.
Miao, F., Chen, Z., Zhang, L., Liu, Z., Wu, X., Yuan, Y. C. et al. (2012). Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. Journal of Biological Chemistry (in press).
74.
Sapienza, C., Lee, J., Powell, J., Erinle, O., Yafai, F., Reichert, J., et al. (2011). DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics, 6, 20–28.PubMedCrossRef
75.
Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011). miRNAs in human cancer. The Journal of Pathology, 223, 102–115.PubMedCrossRef
76.
Fabbri, M. (2010). miRNAs as molecular biomarkers of cancer. Expert Review of Molecular Diagnostics, 10, 435–444.PubMedCrossRef
77.
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., et al. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America, 106, 4402–4407.PubMedCrossRef
78.
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513–10518.PubMedCrossRef
79.
Tijsen, A. J., Creemers, E. E., Moerland, P. D., de Windt, L. J., van der Wal, A. C., Kok, W. E., et al. (2010). MiR423-5p as a circulating biomarker for heart failure. Circulation Research, 106, 1035–1039.PubMedCrossRef
80.
Wang, G., Kwan, B. C., Lai, F. M., Chow, K. M., Kam-Tao Li, P., & Szeto, C. C. (2010). Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Disease Markers, 28, 79–86.PubMed
81.
Neal, C. S., Michael, M. Z., Pimlott, L. K., Yong, T. Y., Li, J. Y., & Gleadle, J. M. (2011). Circulating microRNA expression is reduced in chronic kidney disease. Nephrology, Dialysis, Transplantation, 26, 3794–3802.PubMedCrossRef
82.
Starkey Lewis, P. J., Dear, J., Platt, V., Simpson, K. J., Craig, D. G., Antoine, D. J., et al. (2011). Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology, 54, 1767–1776.PubMedCrossRef
83.
Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896–899.PubMedCrossRef
84.
Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 438, 685–689.PubMedCrossRef
85.
Putta, S., Lanting, L., Sun, G., Lawson, G., Kato, M., & Natarajan, R. (2012). Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology, 23, 458–469.PubMedCrossRef
86.
Sun, L., Zhang, D., Liu, F., Xiang, X., Ling, G., Xiao, L., et al. (2011). Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. The Journal of Pathology, 225, 364–377.PubMedCrossRef
87.
Snove, O., Jr., & Rossi, J. J. (2006). Expressing short hairpin RNAs in vivo. Nature Methods, 3, 689–695.PubMedCrossRef
88.
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007). MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature Methods, 4, 721–726.PubMedCrossRef
89.
Chung, A. C., Huang, X. R., Meng, X., & Lan, H. Y. (2010). miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. Journal of the American Society of Nephrology, 21, 1317–1325.PubMedCrossRef
Metadaten
Titel
MicroRNAs and Diabetic Complications
verfasst von
Rama Natarajan
Sumanth Putta
Mitsuo Kato
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 4/2012
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-012-9368-5

Weitere Artikel der Ausgabe 4/2012

Journal of Cardiovascular Translational Research 4/2012 Zur Ausgabe

OriginalPaper

The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis

OriginalPaper

Cardiac Responses to the Intrapericardial Delivery of Metoprolol: Targeted Delivery Compared to Intravenous Administration

OriginalPaper

The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction

OriginalPaper

Diabetic Cardiovascular Disease: Getting to the Heart of the Matter

OriginalPaper

Haptoglobin Genotype and Its Role in Diabetic Cardiovascular Disease

OriginalPaper

Perspectives on Systems Biology Applications in Diabetic Kidney Disease

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise